CD44‐independent hepatocyte growth factor/c‐Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Glia

• Publication date

  2004-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/glia.10340PMID 14730703
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression

  2003cited by this paper
• CD44: From adhesion molecules to signalling regulators

  2003cited by this paper
• Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1.

  2003influential reference
• HGF/SF‐met signaling in the control of branching morphogenesis and invasion

  2003cited by this paper
• International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.

  2002cited by this paper
• CD44 variant-specific antibodies trigger hemopoiesis by selective release of cytokines from bone marrow macrophages.

  2002cited by this paper
• Malignant peripheral nerve sheath tumours in neurofibromatosis 1

  2002cited by this paper
• CD44 is required for two consecutive steps in HGF/c-Met signaling.

  2002influential reference
• Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components

  2001cited by this paper
• Co-operative Effect of c-Src Tyrosine Kinase and Stat3 in Activation of Hepatocyte Growth Factor Expression in Mammary Carcinoma Cells*

  2001cited by this paper
• Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models

  2001cited by this paper
• Cd44 Enhances Neuregulin Signaling by Schwann Cells

  2000cited by this paper
• Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.

  2000cited by this paper
• Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models.

  2000cited by this paper
• Hepatocyte growth factor, Met, and CD44. Amenage a trois in B cells

  2000cited by this paper
• Role of Src expression and activation in human cancer

  2000cited by this paper
• Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer.

  1999cited by this paper
• Overexpression of activated neu/erbB2 initiates immortalization and malignant transformation of immature Schwann cells in vitro

  1999cited by this paper
• Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas.

  1999cited by this paper
• Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.

  1999cited by this paper
• p53 and Ki-67 Proliferating Cell Nuclear Antigen in Benign and Malignant Peripheral Nerve Sheath Tumors in Children

  1999cited by this paper
• Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.

  1999cited by this paper
• c-Src Kinase Activity Is Required for Hepatocyte Growth Factor-induced Motility and Anchorage-independent Growth of Mammary Carcinoma Cells*

  1998cited by this paper
• Neoplasms with neural differentiation: a review. Part II: Malignant neoplasms.

  1998cited by this paper
• Malignant peripheral nerve sheath tumor: analysis of treatment outcome.

  1998cited by this paper
• Coexpression of HGF and c‐Met/HGF receptor in human bone and soft tissue tumors

  1998cited by this paper
• Plexiform neurofibroma with and without associated malignant peripheral nerve sheath tumor: a clinicopathologic and immunohistochemical analysis of 54 cases.

  1998cited by this paper
• Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in humans.

  1998cited by this paper
• Hepatocyte growth factor and c-MET in benign and malignant peripheral nerve sheath tumors.

  1997cited by this paper
• AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44

  1997influential reference
• CD44 expression is aberrant in benign Schwann cell tumors possessing mutations in the neurofibromatosis type 2, but not type 1, gene.

  1997influential reference
• Activation of Hepatocyte Growth Factor in the Injured Tissues Is Mediated by Hepatocyte Growth Factor Activator (*)

  1996cited by this paper
• p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors.

  1996cited by this paper
• Hepatocyte growth factor is a mitogen for Schwann cells and is present in neurofibromas

  1994cited by this paper
• Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII.

  1993cited by this paper
• Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis.

  1992cited by this paper
• Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer.

  1992cited by this paper
• Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.

  1992cited by this paper
• Structure‐function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding.

  1992cited by this paper
• A Case of Neurofibrosarcoma Associated with Neurofibromatosis: Light Microscopic, Ultrastructural, Immunohistochemical and Biochemical Investigations

  1990cited by this paper
• Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis.

  1990cited by this paper
• Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference.

  1988cited by this paper
• Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases

  1986cited by this paper
• Malignant schwannoma—Clinical characteristics, survival, and response to therapy

  1981cited by this paper
• Malignant schwannoma. A Clinicopathologic Study

  1973cited by this paper
• Survival in malignant schwannoma. An 18‐year study

  1971cited by this paper
• The FASEB Journal express article 10.1096/fj.01-0421fje. Published online November 29, 2001.

  year unknowncited by this paper

• Degenerative and cognitive diseases.

  2023cites this paper
• Frequently amplified c-MET and STAT3 signalling drives malignant peripheral nerve sheath tumour (MPNST) cell migration, invasion and tumour formation

  2022cites this paper
• Neurofibroma Development in Neurofibromatosis Type 1: Insights from Cellular Origin and Schwann Cell Lineage Development

  2022cites this paper
• The clinico-pathologic profile of primary and recurrent orbital/periorbital plexiform neurofibromas (OPPN)

  2021cites this paper
• Peripheral Nerve Sheath Tumors of the Orbit

  2020cites this paper
• Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms.

  2018cites this paper
• CD44 Transmembrane Receptor and Hyaluronan Regulate Adult Hippocampal Neural Stem Cell Quiescence and Differentiation*

  2017cites this paper
• Radiation-Induced Malignant Peripheral Nerve Sheath Tumors: A Systematic Review.

  2017cites this paper
• Identification of biomarkers for development of NF1-associated malignant peripheral nerve sheath tumours

  2015cites this paper
• Soluble AXL: A Possible Circulating Biomarker for Neurofibromatosis Type 1 Related Tumor Burden

  2014cites this paper
• Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor

  2014cites this paper
• Activation of c-Met and Upregulation of CD44 Expression Are Associated with the Metastatic Phenotype in the Colorectal Cancer Liver Metastasis Model

  2014cites this paper
• Targetable Mediator of Antiangiogenic Therapy Resistance

  2013cites this paper
• Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance

  2013cites this paper
• Malignant Peripheral Nerve Sheath Tumors: Prognostic and Diagnostic Markers and Therapeutic Targets

  2012cites this paper
• Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors

  2011influential citation
• Human Cancer Biology Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors

  2011influential citation
• Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).

  2011cites this paper
• Gene Expression Analysis Identifies Potential Biomarkers of Neurofibromatosis Type 1 Including Adrenomedullin

  2010cites this paper
• Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo

  2010cites this paper
• CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration.

  2010cites this paper
• CD44-independent activation of the Met signaling pathway by HGF and InlB.

  2010cites this paper
• CD44 and hyaluronan promote invasive growth of B35 neuroblastoma cells into the brain.

  2010cites this paper
• Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin Running Title: Adrenomedullin as an NF1 serum biomarker

  2010cites this paper
• Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides.

  2009cites this paper
• Neuregulin‐1β and neuregulin‐1α differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells

  2009cites this paper
• How does the Schwann cell lineage form tumors in NF1?

  2008cites this paper
• Award Number: W81XWH-06-1-0293 TITLE: Characterization of Neurofibromas of the Skin and Spinal Roots in a Mouse Model

  2008cites this paper
• Influence of hormones and hormone metabolites on the growth of schwann cells derived from embryonic stem cells and on tumor cell lines expressing variable levels of neurofibromin

  2008cites this paper
• Malignant peripheral nerve sheath tumor: Molecular pathogenesis and current management considerations

  2008cites this paper
• Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB

  2007cites this paper
• Mice with GFAP‐targeted loss of neurofibromin demonstrate increased axonal MET expression with aging

  2007influential citation
• Establishment of three malignant peripheral nerve sheath tumor cell lines, FU-SFT8611, 8710 and 9817: conventional and molecular cytogenetic characterization.

  2006cites this paper
• C-met Induction in the Hippocampus of NF1-Null Mice

  2006cites this paper
• Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.

  2006cites this paper
• Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.

  2006cites this paper
• Pro-Invasive Molecular Cross-Signaling between Cancer Cells and Myofibroblasts

  2006cites this paper
• Tumor Suppressor Mutations and Growth Factor Signaling in the Pathogenesis of NF1-Associated Peripheral Nerve Sheath Tumors: II. The Role of Dysregulated Growth Factor Signaling

  2005cites this paper
• Hepatocyte growth factor, its receptor, and their potential value in cancer therapies.

  2005cites this paper
• CD44 overexpression by oligodendrocytes: A novel mouse model of inflammation‐independent demyelination and dysmyelination

  2004cites this paper